Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab for HCT-associated TMA
NCT03518203Phase 2Completed
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Aug 2018
- Primary completion
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eculizumab in thrombotic microangiopathy (TMA) and atypical hemolytic uremic syndrome (aHUS), sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoint: Survival at 6 months. Started Aug 2018; status: completed.
02
Drugs
eculizumab
03
Conditions
thrombotic microangiopathy (TMA)atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on NCT03518203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03518203.